Year: 2025

The share repurchase programme runs as from 26 February 2025 and up to and including 30 January 2026 at the latest. In this period, Jyske Bank will acquire shares with a value of up to DKK 2.25 billion, cf. Corporate Announcement No. 3/2025 of 26 February 2025. The share repurchase programme is initiated and structured in compliance with the EU Commission Regulation No. 596/2014 of 16 April 2014, the so-called “Market Abuse Regulation”, and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (together with the Market Abuse Regulation, the “Safe Harbour Rules”). The following transactions have been made under the program:  Number of shares Average purchase price (DKK) Transaction value (DKK)Accumulated, previous announcement 705,173 529.33 373,267,66114 April 2025 21,247 504.46 10,718,23415 April...

Aspocomp Group Plc, Investor News, April 22, 2025, at 9:35 a.m. Finnish time Aspocomp will publish its Interim Report for January-March 2025 on Tuesday April 29, 2025 at around 8:00 a.m. Finnish time. Aspocomp’s CEO Manu Skyttä will present January-March Interim Report in a webcast on the same day starting at 1:00 p.m. Finnish time. The webcast will be held in Finnish and can be accessed at  https://aspocomp.events.inderes.com/q1-2025. Questions are requested to be submitted in writing via the chat functionality of the webcast portal. The presentation material and a recording of the webcast (in Finnish) will be available at Aspocomp’s website https://aspocomp.com/investors/interim-reports/reports/. For further information, please contact Manu Skyttä, President and CEO, tel. +358 20 775 6860, manu.skytta(at)aspocomp.com. Aspocomp...

Antwerp, April 22, 2025 (GLOBE NEWSWIRE) — CMB.TECH NV (NYSE: CMBT & Euronext: CMBT) (“CMB.TECH” or the “Company”) invites its shareholders to participate in the Annual General Meeting, Special General Meeting & Extraordinary General Meeting that will be held on Thursday 22 May 2025 at 10.00 a.m. CET in 2000 Antwerp, De Gerlachekaai 20. In view of the record date of Thursday 8 May 2025, shareholders may not reposition shares between the Belgian Register and the U.S. Register during the period from Wednesday 7 May 2025 at 8.00 a.m. (Belgian time) until Friday 9 May 2025 at 8.00 a.m. (Belgian time) (“Freeze Period”). The convening notice and other documents related to these meetings are available on the CMB.TECH website in the investors section under General Meetings.  The practical formalities for participation in this...

Press release VALLOUREC WINS A NEW MAJOR LINE PIPE CONTRACT FOR BRAZIL’S BUZIOS OFFSHORE FIELD Meudon (France), April 22, 2025 – Vallourec, a world leader in premium seamless tubular solutions, announces today that it has secured a major contract with Allseas to supply line pipes for Búzios 10 offshore project located at the Búzios field, operated by Petrobras. This contract represents nearly 18,000 tons of subsea seamless premium carbon steel line pipes, for the risers and flowlines. The contract includes an optional scope of almost 5,000 tons. Located off the coast of Rio de Janeiro, Búzios is one of the world’s largest deepwater fields. This field represents a significant part of the Brazilian oil company’s operations. The field’s production is expected to substantially increase as five additional units are set to...

Oslo, Norway, 22 April 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, has successfully developed, scaled and automated its proprietary manufacturing process for its TCR-NK cell therapies. This milestone represents a major advancement in the Company’s preparation for clinical entry to provide life-changing, innovative treatments for patients battling cancer. The proprietary manufacturing process is applicable to any product emerging from the Company’s pipeline which means any TCR-NK product can be plugged into the established manufacturing process strengthening Zelluna’s dominance of the TCR-NK therapeutic field. Establishing and locking down a manufacturing process marks an essential step towards the production of TCR-NK cell therapies...

The management board of TextMagic AS proposed to the shareholders to adopt a resolution without convening a general meeting. The notice was published on April 4, 2025 in the stock exchange information system of Nasdaq Tallinn and on the same day on the Company’s website and in the newspaper “Eesti Päevaleht”. The list of shareholders entitled to vote was fixed on April 14, 2025 at the end of the business day of the Nasdaq CSD settlement system and the voting took place in the period April 4, 2025 – April 21, 2025. A total of 2 shareholders of the Company, whose shares represent 7,362,089 votes, representing a total of 85.51% of the votes, casted their votes on time, i.e. by April 21, 2025 at 12:00 (GMT +3). If a shareholder abstained, he/she was deemed to have voted against the resolution. The shareholders of the Company adopted...

TAIPEI, Taiwan, April 21, 2025 (GLOBE NEWSWIRE) — AP Biosciences, a clinical-stage biopharmaceutical company dedicated to transforming cancer therapy through innovative bispecific antibodies, today announced that it will present a preclinical abstract in a poster presentation at the upcoming American Association for Cancer Research (AACR) Association Annual Meeting, taking place in Chicago, IL, April 25- 30, 2025.  The data will showcase the potential of AP402, a first-in-class, next generation T cell engager targeting CD137 and p95HER2 in in-vivo and in vitro studies. AP402 recently received IND clearance to begin clinical trials in Australia this past February. Details for the poster presentation are as follows:   Title: AP402, a bispecific antibody targets p95HER2 and CD137, shows a potent antitumor activityPoster Number: 6016Presenter:...

Newport Beach, Calif., April 21, 2025 (GLOBE NEWSWIRE) — GivBux, Inc. (OTC: GBUX) (“GivBux” or the Company”), a publicly traded Super App and charitable giving platform, today announced the finalized terms of its previously approved special dividend for shareholders. The Board of Directors has confirmed that the dividend will consist of warrants issued on a 1-for-10 basis, granting shareholders the right to purchase one share of GivBux common stock for every 10 shares owned. Each warrant will be exercisable at $4.00 per share, subject to the terms and conditions outlined in the Company’s Warrant Agreement. The ex-dividend date will be May 15, 2025 with a distribution date of May 21, 2025. The warrants are expected to provide shareholders with a unique opportunity to participate in the potential future growth of...